ImmuVen's Grant - III Round

ImmuVen raised a round of funding on May 01, 2012. Investors include National Institute of Allergy and Infectious Diseases.

ImmuVen develops drugs that can be used to treat infectious diseases and cancer. The company features life science technology, T cell receptors, a unique class of immune-targeting therapeutic and diag…

Articles about ImmuVen's Grant - III Round: